分子診断市場：技術、製品、用途、エンドユーザー別-2025～2030年の世界予測

分子診断市場は、2023年に315億9,000万米ドルと評価され、2024年には363億米ドルに達すると予測され、CAGR 15.82％で成長し、2030年には883億6,000万米ドルに達すると予測されています。

分子診断の対象範囲には、遺伝物質やタンパク質を分析する分子生物学的手法を利用して、疾患の診断やモニタリング、特定の疾患の発症リスクの評価、予後の判定を行う幅広い検査が含まれます。個別化医療における重要なツールとして、その必要性は、早期かつ正確な診断を提供し、オーダーメイドの治療戦略を可能にする精度と能力にあります。分子診断は、感染症検出、腫瘍学、遺伝子検査、薬理ゲノミクスに応用され、病院、研究所、研究機関、製薬会社などのエンドユーザーに供給されます。この市場は、感染症やがんの増加、分子診断技術の技術的進歩、個別化医療への関心の高まりなどの影響を受けています。

最近のビジネス機会は、人工知能と機械学習を診断プラットフォームに統合し、データ分析と予測能力を強化することから生まれています。アッセイ開発のための戦略的提携や、パンデミック対策における政府資金の増加も成長の道を示しています。しかし、検査コストの高さ、規制当局の承認の厳しさ、先進的インフラの必要性などによる制約があり、特にリソースの乏しい環境での導入が制限される可能性があります。標準化されたプロトコルを開拓し、新興国市場でのアクセスを改善することは、こうした課題に対処するための重要なステップです。

イノベーションの可能性があるセグメントとしては、ポイントオブケア検査ソリューション、費用対効果の高いシークエンシング技術、新規診断検査につながるバイオマーカー探索などがあります。バイオテクノロジー企業と医療プロバイダーのパートナーシップは、これらのイノベーションの開発と実施を促進することができます。分子診断市場は本質的にダイナミックであり、急速な技術進化と医療におけるより診断中心のアプローチへのシフトが原動力となっています。企業は、希少疾患を含むアッセイポートフォリオの拡大に注力し、デジタルヘルス技術を活用してワークフローを最適化し、患者の転帰を改善することで、戦略的なポジションを確立することができます。急成長する科学の進歩や規制状況に適応し続けることが、このセグメントでの事業成長を持続させる鍵となります。

市場力学：急速に進化する分子診断市場の主要市場洞察を公開

分子診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 感染症と各種がんの高い有病率院内感染の有病率
  • 政府助成金の増加
  • ポイントオブケア診断に対する需要の増加
• 市場抑制要因
  • 明確で統一された規制の枠組みの欠如
  • 新しい分子診断技術の適切な使用を制限する訓練された専門家の非効率性
• 市場機会
  • 分子診断における技術の進歩、疾患の早期診断に対する意識の高まり
  • 新興国における研究開発活動の活発化
• 市場課題
  • 新しい分子診断検査の承認の遅れ
  • 承認プロセスに関する厳しい規制

ポーターのファイブフォース：分子診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：分子診断市場における外部からの影響の把握

外部マクロ環境要因は、分子診断市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：分子診断市場における競合情勢の把握

分子診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：分子診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、分子診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：分子診断市場における成功への道筋を描く

分子診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 感染症や各種がんの蔓延率の高さ、院内感染の蔓延率
    • 政府資金の増額
    • ポイントオブケア診断の需要増加
  • 抑制要因
    • 明確で統一された規制枠組みの欠如
    • 訓練を受けた専門家の非効率性が、新しい分子診断技術の適切な使用を制限している
  • 機会
    • 分子診断の技術進歩と病気の早期診断への意識の高まり
    • 新興国における研究開発活動の増加
  • 課題
    • 新しい分子診断検査の承認の遅れ
    • 承認プロセスに関連する厳格な規制
• 市場セグメンテーション分析
  • 技術：次世代シーケンシングの個別化医療と標的治療への利用拡大
  • 用途：感染症の早期介入のための精密医療における分子診断の統合
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 分子診断市場：技術別

• イントロダクション
• チップとマイクロアレイ
• in situハイブリダイゼーション
• 質量分析（MS）
• PCR
• シーケンシング

第7章 分子診断市場：製品別

• イントロダクション
• 機器
• 試薬

第8章 分子診断市場：用途別

• イントロダクション
• 血液検査
• 遺伝性疾患スクリーニング
• ヒト白血球抗原タイピング
• 感染症
• 微生物学
• 腫瘍学
• 薬理ゲノム学

第9章 分子診断市場：エンドユーザー別

• イントロダクション
• 病院
• 研究所

第10章 南北アメリカの分子診断市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の分子診断市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの分子診断市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Guardant Health、約500のバイオマーカーを備えたGuardant360 TissueNext検査を開始
  • QIAGENとMyriad Geneticsが世界的に利用される相同組換え欠損検査で提携
  • Labcorp、大腸がんの早期段階に臨床的に検証されたctDNAソリューションを発売
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• ADT BIoTech
• Agilent Technologies Inc.
• Becton, Dickinson, and Company
• Bio-Rad Laboratories, Inc.
• Biocartis Group NV
• bioMerieux SA
• Danaher Corporation
• DiaSorin S.p.A.
• Grifols S.A.
• Hologic Inc.
• Illumina, Inc.
• Johnson & Johnson
• LabCorp
• Myriad Genetics, Inc.
• Novartis AG
• Roche Diagnostics Corporation
• Siemens Healthineers
• Sysmex Corporation by Oxford Gene Technology
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. MOLECULAR DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. MOLECULAR DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MOLECULAR DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CHIPS AND MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY (MS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC DISEASE SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HUMAN LEUKOCYTE ANTIGEN TYPING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 40. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 152. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 158. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 196. MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Molecular Diagnostics Market was valued at USD 31.59 billion in 2023, expected to reach USD 36.30 billion in 2024, and is projected to grow at a CAGR of 15.82%, to USD 88.36 billion by 2030.

The scope of molecular diagnostics encompasses a wide range of tests that utilize molecular biology techniques to analyze genetic material and proteins to diagnose and monitor diseases, assess the risk of developing certain conditions, and determine prognosis. As a crucial tool in personalized medicine, its necessity lies in its precision and ability to provide early and accurate diagnosis, enabling tailored therapeutic strategies. Molecular diagnostics find applications in infectious disease detection, oncology, genetic testing, and pharmacogenomics, catering to end-users such as hospitals, laboratories, research institutions, and pharmaceutical companies. The market is influenced by increasing incidences of infectious diseases and cancer, technological advancements in molecular diagnostic techniques, and a growing focus on personalized medicine.

Recent opportunities emerge from the integration of artificial intelligence and machine learning with diagnostic platforms, enhancing data analysis and predictive capabilities. Strategic collaborations for assay development and increased government funding in pandemic preparedness also present growth avenues. However, the market faces limitations due to high costs of tests, stringent regulatory approvals, and the need for sophisticated infrastructure, which can restrict adoption particularly in low-resource settings. Developing standardized protocols and improving access in emerging markets are crucial steps to addressing these challenges.

Innovation areas with potential include point-of-care testing solutions, cost-effective sequencing technologies, and biomarker discovery that can lead to novel diagnostic tests. Partnerships between biotech firms and healthcare providers can expedite the development and implementation of these innovations. The molecular diagnostics market is intrinsically dynamic, driven by rapid technological evolution and a shift towards a more diagnostic-centric approach in healthcare. Businesses can strategically position themselves by focusing on expanding their assay portfolios to include rare diseases and by leveraging digital health technologies to optimize workflows and improve patient outcomes. Remaining adaptable to burgeoning scientific advancements and regulatory landscapes will be key to sustaining business growth in this field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Molecular Diagnostics Market

The Molecular Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High prevalence of infectious diseases and various types of cancers prevalence rate of hospital-acquired infections
  • Escalation in government funding
  • Increasing demand for point of care diagnostics
• Market Restraints
  • Lack of clear and uniform regulatory framework
  • Inefficiency of trained professionals limiting the appropriate use of new molecular diagnostic technologies
• Market Opportunities
  • Technological advancements in molecular diagnostics along with increasing awareness towards early disease diagnosis
  • Rising number of R&D activities in the emerging economies
• Market Challenges
  • Delay in the approval of new molecular diagnostic tests
  • Stringent regulations associated with the approval process

Porter's Five Forces: A Strategic Tool for Navigating the Molecular Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Molecular Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Molecular Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Molecular Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Molecular Diagnostics Market

A detailed market share analysis in the Molecular Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Molecular Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Molecular Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Molecular Diagnostics Market

A strategic analysis of the Molecular Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ADT Biotech, Agilent Technologies Inc., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Biocartis Group NV, bioMerieux SA, Danaher Corporation, DiaSorin S.p.A., Grifols S.A., Hologic Inc., Illumina, Inc., Johnson & Johnson, LabCorp, Myriad Genetics, Inc., Novartis AG, Roche Diagnostics Corporation, Siemens Healthineers, Sysmex Corporation by Oxford Gene Technology, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Chips and Microarrays, In Situ Hybridization, Mass Spectrometry (MS), PCR, and Sequencing.
• Based on Product, market is studied across Instruments and Reagents.
• Based on Application, market is studied across Blood Screening, Genetic Disease Screening, Human Leukocyte Antigen Typing, Infectious Disease, Microbiology, Oncology, and Pharmacogenomics.
• Based on End User, market is studied across Hospitals and Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High prevalence of infectious diseases and various types of cancers prevalence rate of hospital-acquired infections
    • 5.1.1.2. Escalation in government funding
    • 5.1.1.3. Increasing demand for point of care diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of clear and uniform regulatory framework
    • 5.1.2.2. Inefficiency of trained professionals limiting the appropriate use of new molecular diagnostic technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in molecular diagnostics along with increasing awareness towards early disease diagnosis
    • 5.1.3.2. Rising number of R&D activities in the emerging economies
  • 5.1.4. Challenges
    • 5.1.4.1. Delay in the approval of new molecular diagnostic tests
    • 5.1.4.2. Stringent regulations associated with the approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Expanding use of next-generation sequencing in personalized medicine and targeted therapies
  • 5.2.2. Applications: Integration of molecular diagnostics in precision medicine for early intervention of infectious diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Molecular Diagnostics Market, by Technology

• 6.1. Introduction
• 6.2. Chips and Microarrays
• 6.3. In Situ Hybridization
• 6.4. Mass Spectrometry (MS)
• 6.5. PCR
• 6.6. Sequencing

7. Molecular Diagnostics Market, by Product

• 7.1. Introduction
• 7.2. Instruments
• 7.3. Reagents

8. Molecular Diagnostics Market, by Application

• 8.1. Introduction
• 8.2. Blood Screening
• 8.3. Genetic Disease Screening
• 8.4. Human Leukocyte Antigen Typing
• 8.5. Infectious Disease
• 8.6. Microbiology
• 8.7. Oncology
• 8.8. Pharmacogenomics

9. Molecular Diagnostics Market, by End User

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Laboratories

10. Americas Molecular Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Molecular Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Molecular Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Guardant Health launches Guardant360 TissueNext test with nearly 500 biomarkers
  • 13.3.2. QIAGEN and Myriad Genetics collaborate on Homologous Recombination Deficiency Test for Global Use
  • 13.3.3. Labcorp launches clinically validated ctDNA solution for early-stage colon cancer
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ADT Biotech
• 3. Agilent Technologies Inc.
• 4. Becton, Dickinson, and Company
• 5. Bio-Rad Laboratories, Inc.
• 6. Biocartis Group NV
• 7. bioMerieux SA
• 8. Danaher Corporation
• 9. DiaSorin S.p.A.
• 10. Grifols S.A.
• 11. Hologic Inc.
• 12. Illumina, Inc.
• 13. Johnson & Johnson
• 14. LabCorp
• 15. Myriad Genetics, Inc.
• 16. Novartis AG
• 17. Roche Diagnostics Corporation
• 18. Siemens Healthineers
• 19. Sysmex Corporation by Oxford Gene Technology
• 20. Thermo Fisher Scientific Inc.